---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-030640"
form_type: "8-K"
ticker: "ELAB"
cik: "0001840563"
company_name: "PMGC Holdings Inc."
filed_at: "2025-04-10T23:59:59+00:00"
generated_at: "2026-05-23T17:25:58.305259+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "medium"
source: SEC EDGAR
---

# PMGC subsidiary Northstrive licenses Yuva Biosciences' AI platform for obesity and cardiometabolic drugs

## Summary
- Northstrive (PMGC subsidiary, ticker ELAB) signs exclusive worldwide license for therapies in cardiac diseases and obesity.
- YuvaBio to use its AI platform MitoNova to identify small molecule candidates targeting mitochondrial health.
- Upfront fee, development milestone payments, and tiered royalties on net sales; no specific dollar amounts disclosed.
- Multi-phase program includes in silico modeling, virtual screening, and wet-lab validation to shortlist candidates.
- Agreement covers multi-year term; Northstrive may terminate for convenience with early termination fee.

## SEC filing metadata
- accession: 0001213900-25-030640
- form_type: 8-K
- ticker: ELAB
- cik: 0001840563
- company_name: PMGC Holdings Inc.
- filed_at: 2025-04-10T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840563/000121390025030640/0001213900-25-030640-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840563/000121390025030640/ea0237224-8k_pmgchold.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-030640
- JSON: https://secwatch.observer/filing/0001213900-25-030640.json
- Plain text: https://secwatch.observer/filing/0001213900-25-030640.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.